Record mula sa primary source
MateryalIba pa
Nakumpleto ng Aquestive ang FDA Type A meeting para sa Anaphylm NDA resubmission
Nakumpleto ng kumpanya ang in-person Type A meeting sa FDA at nakatanggap ng preliminary comments tungkol sa resubmission ng kanilang NDA para sa Anaphylm (dibutepinephrine) sublingual film. Nagbibigay ang meeting na ito ng regulatory feedback bago ang planadong NDA resubmission para sa paggamot ng Type 1 allergic reactions kabilang ang anaphylaxis.
Mahahalagang fact
- Na-file
- Mar 30, 2026, 11:44 AM
- Kaganapan
- Iba pa
- Direksyon
- Neutral
- Kumpanya
AQSTAquestive- Asset
- epinephrine
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
aqst-20260330 0001398733 false 0001398733 2026-03-30 2026-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2026 Aquestive Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38599 82-3827296 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 30 Technology Drive Warren , NJ 07059 ( 908 ) 941-1900 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Not Applicable (Former name or former address, if changed since last report) _______________________
Higit pa tungkol sa asset na ito
Decision-grade
Ago 10, 2026
11:05 AM
AQSTAquestiveDecision-grade
May 13, 2026
08:04 PM
AQSTAquestiveDecision-grade
Ene 9, 2026
12:18 PM
AQSTAquestiveDecision-grade
Nob 5, 2025
09:04 PM
AQSTAquestiveKapansin-pansin
Okt 8, 2025
11:23 AM
AQSTAquestiveAquestive: dalawang bagong patent ang nagpapahaba ng proteksyon ng Anaphylm hanggang 2037